Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, has gained a monumental increase of 5.65% in aftermarket trading session. As a result, AEZS stock is trading at $0.52 at the time of the writing. On Thursday, AEZS closed the day at $0.49 after increasing 4.66% during regular trading hours. The increase has come despite no apparent news or press release which could have prompted that. So for the moment, let’s discuss its recent developments.
AEZS Q3 2021 Operational Results
On 4th November, AEZS released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $0.6 million during the quarter against $0.1 million for the same period of 2020. The total operating expenses bore by the company during the quarter were $2.4 million against $1.9 million for the same quarter of 2020. The net finance income generated by the company during the period was $0.1 million against $0.6 million for the same period of 2020. The consolidated net loss suffered by the company during the period was $1.7 million (or $0.01 per common share) against $0.01 per common share) against $11 million (or $0.02 per common share) for the same period of 2020.
AEZS: Business Highlights
Alongside the operational results, AEZS also reported recent business highlights. The company had entered into an exclusive license with Julius-Maximilians-University of Wuerzburg. The license was about the early pre-clinical development of AIM Biologics which could prove handy in the treatment of Parkinson’s disease. The company also exercised its option to expand the application of the oral vaccine platform to chlamydia under the agreement.
Executive Commentary
Dr. Klaus Paulini, Chief Executive Officer of AEZS, while commenting on the results said that since the start of the year, the company had concerted efforts not only to advance its clinical-stage program but also to expand its development pipeline. He said that the company is diligently working to execute the advancements of all its clinical and pre-clinical programs and is poised to continue building value in the long term.
Future Outlook for AEZS
During the last three months, AEZS stock has declined more than 30%. However, recent performances depict that the stock is a hot and popular entity among investors. So, potential investors should keep a close eye on the developments related to AEZS stock to reap the upcoming benefits.
